Clinical Scorecard: The Evolving MIGS Pipeline
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Minimally invasive approaches to lower intraocular pressure (IOP) through various devices and techniques. |
| Target Population | Patients with glaucoma requiring surgical intervention. |
| Care Setting | Ophthalmology clinics and surgical centers. |
Key Highlights
- Investigational devices include sustained-release drug delivery systems and laser-based procedures.
- New stents and shunts are being developed to enhance aqueous outflow.
- Technical innovation faces regulatory and reimbursement challenges.
Guideline-Based Recommendations
Diagnosis
- Utilize comprehensive eye examinations to assess glaucoma severity.
Management
- Consider minimally invasive glaucoma surgery (MIGS) for appropriate patients.
Monitoring & Follow-up
- Regular follow-up to assess intraocular pressure and visual field changes.
Risks
- Potential complications from surgical procedures and device implantation.
Patient & Prescribing Data
Patients with glaucoma, particularly those who may benefit from reduced reliance on topical medications.
Sustained-release systems like iDose TREX and BIM-IOL aim to improve adherence and reduce medication burden.
Clinical Best Practices
- Engage with FDA to define clinically meaningful endpoints for new technologies.
- Advocate for regulatory and reimbursement frameworks to facilitate access to new devices.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.